Retinitis Pigmentosa Research
Argus II Implant post-market study for retinitis pigmentosa (RP)
We are conducting a five-year post-market study of Argus™ II retinal implant system by Second Sight. After implanting an artificial retina in patients, we are testing their ability to detect light and dark in the environment. This study is meant to determine the effectiveness of Argus II and how patients can use the device to function in their daily lives.
Optogenetics gene therapy to provide low vision
We are using gene therapy to insert a light sensitive pigment into retinal ganglion cells. Our goal is to provide low vision to patients who are otherwise blind from retinitis pigmentosa.
Retinitis Pigmentosa natural history study of patients with the P23H mutation of the Rhodopsin gene
We are currently working on a natural history study of qualified patients with the P23H mutation of the Rhodopsin gene (RHONHS). We are learning the rate of disease progression in a group of patients with this particular genetic mutation.
X-linked retinitis pigmentosa natural history studies
We are enrolling qualified patients with x-linked retinitis pigmentosa in order to measure disease progression in a group of patients with this disease.
X-linked retinitis pigmentosa gene therapy trials
Qualifying patients may enter a gene therapy trial in an attempt to slow or halt visual loss
In order to be seen at the Retina Foundation of the Southwest, you must have a referral from your ophthalmologist.
If you have a question related to retinitis pigmentosa, please contact us at 214-363-3911.
Related ArticlesRetina Foundation Launches Cutting-Edge Artificial Intelligence Project Retina Foundation to Conduct First Optogenetics Gene Therapy Clinical Trial International Partnership for Lazy Eye Detection and Treatment iPad Games Could Be the Future Lazy Eye Treatment An iPhone App to Monitor Eye Disease